Long-term evaluation of lung function in patients affected by scleroderma treated with cyclic iloprost infusions

Rheumatology International

Volumn 25, Issue 4, 2005, Pages 250-254

  Caramaschi, Paola ^a,b   Biasi, Domenico ^a   Ferrari, Marcello ^a   Volpe, Alessandro ^a   Martinelli, Nicola ^a   Carletto, Antonio ^a   Dal Forno, Paola ^a   Bambara, Lisa Maria ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b Dipartimento di Medicina Clinica e Sperimentale   (Italy)

Author keywords

Iloprost; Lung function; Scleroderma

Indexed keywords

CARBON MONOXIDE; CYCLOPHOSPHAMIDE; ILOPROST; PENICILLAMINE; PREDNISONE; STEROID;

ADULT; ARTICLE; BLOOD DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DRUG INFUSION; FEMALE; FLUSHING; FUNCTIONAL ASSESSMENT; HEADACHE; HEART ARRHYTHMIA; HUMAN; KIDNEY DISEASE; LIVER DISEASE; LUNG ARTERY PRESSURE; LUNG CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; NAUSEA; PARAMETER; PATIENT; PREDICTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCLERODERMA; SIDE EFFECT; SPIROMETRY; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ADULT; ECHOCARDIOGRAPHY, DOPPLER, COLOR; FEMALE; HUMANS; ILOPROST; INFUSIONS, INTRAVENOUS; LUNG; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; SCLERODERMA, LIMITED; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 20044395814     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-004-0439-z     Document Type: Article

References (25)

1. Bryan C, Howard Y, Brennan P, Black CM, Silman A (1996) Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population. Br J Rheumatol 35:1122-1126
2. LeRoy EC, Krieg T, Black CM, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202-205
3. Steen VD, Medsger TA (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437-2444
4. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C (1993) Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20:838-844
5. Steen VD, Lanz JK, Conte C, Owens GR, Medsger TA (1994) Therapy for severe interstitial lung disease in systemic sclerosis: a retrospective study. Arthritis Rheum 37:1290-1296
6. Akesson A, Scheja A, Lundin A, Wollheim FA (1994) Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 37:729-735
7. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jobsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA Jr (2000) Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 132:425-434
8. Torley HJ, Madhok R, Capell Ha, Brouwer RML, Maddison PJ, Black CM, Englert H, Dormandy JA, Watson HR (1991) A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases. Ann Rheum Dis 50:800-804
9. Wigley FM, Wise RA, Seibold JR, McCloskey DA, Dole WP (1994) Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. Ann Intern Med 120:199-206
10. Watson HR, Belcher G (1991) Retrospective comparison of iloprost with other treatments for secondary Raynaud's phenomenon. Ann Rheum Dis 50:359-361
11. Della Bella S, Molteni M, Mocellin C, Fumagalli S, Bonara P, Scorza R (2001) Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins Other Lipid Mediat 65:73-83
12. Filaci G, Cutolo M, Scudeletti M, Castagneto C, Derchi L, Gianrossi R, Ropolo F, Zentilin P, Sulli A, Murdaca G, Ghio M, Indiveri F, Puppo F (1999) Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. Rheumatology 38:992-996
13. Della Bella S, Molteni M, Mascagni B, Zulian C, Compasso S, Scorza R (1997) Cytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine. Clin Exp Rheumatol 15:135-141
14. Kahari V, Heini J, Vuorio E (1987) Interleukin 1 increases collagen production and mRNA levels in cultured skin fibroblasts. Biochem Biophys Acta 929:142-147
15. Duncan M, Berman B (1991) Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 97:686-692
16. Rademaker M, Thomas RH, Provost G, Beachman JA, Cooke ED, Kirby JD (1987) Prolonged increase in digital blood flow following iloprost infusion in patients with systemic sclerosis. Postgrad Med J 63:617-620
17. Quanjer PH (1983) Standardized lung function testing. Report of the European Community Working Party for Coal and Steel. Bull Europ Physiopath Respir 19 [Suppl 5]:1-82
18. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, Harris CA, Jablonska S, Jayson MIV, Jimenez SA, Krieg T, Leroy EC, Maddison PJ, Russell ML, Schachter RK, Wollheim FA, Zacharia H (1999) A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 26:2159-2167
19. Schneider PD, Wise RA, Hochberg MC, Wigley FM (1982) Serial pulmonary function in systemic sclerosis. Am J Med 73:385-394
20. Greenwald GI, Tashkin DP, Gong H, Simmons M, Duann S, Furst DE, Clements P (1987) Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study. Am J Med 83:83-92
21. Steen VD, Conte C, Owens GR, Medsger TA Jr (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37:1283-1289
22. Steen VD, Graham G, Conte C, Owens GR, Medsger TA Jr (1992) Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 35:765-770
23. Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E, Arpaia G, Sardina M, Origgi L, Vanoli M (2001) Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol 19:503-508
24. Thurm CA, Wigley FM, Dole WP, Wise RA (1991) Failure of vasodilator infusion to alter pulmonary diffusing capacity in systemic sclerosis. Am J Med 90:547-552
25. Magliano M, Isenberg DA, Hillson J (2002) Pulmonary hypertension in autoimmune rheumatic diseases. Where are we now? Arthritis Rheum 46:1997-2009